PEGS Europe 2010 | Day 1 | Day 2

WEDNESDAY, 6 OCTOBER

13:00 Conference Registration

14:00 Chairperson’s Remarks

Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME

14:05 Recombinant Human Multi-Domain Fusion Proteins

Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME

Activated and dysregulated macrophages play a decisive role in the development of numerous inflammatory processes including progression of cancer. We have generated novel recombinant multi-domain immunotherapeutics by fusing different cytotoxic enzymes to a single chain fragment derived from the CD64-specific human antibody H22. Final aim is the application of tailor-made immunofusions not only considering the targeting moiety, but also the appropriate cytotoxic agent to specifically destroy diseased cells.

14:35 Antibodies-Conjugated Nanoparticles for Targeted Drug Delivery

Roland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart

Nanoparticles such as liposomes and polymers are versatile carrier systems for delivery of therapeutic molecules, e.g. chemotherapeutic drugs, siRNA and proteins. Conjugation of antibodies, antibody fragments or antibody-mimetic scaffolds to the particle surface allow for active delivery to target cells, e.g. for tumor therapy. Binding to target cells has been shown to promote intracellular uptake and can improve selectivity and therapeutic efficacy. Examples for the generation and application of various targeted nanoparticulate drug carriers will be presented.

15:05 Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination with Empowered Rune Nilsson Antibodies in a Syngeneic Rat Tumor Model

Rune Nilsson, Ph.D., Associate Professor, Department of Oncology, Lund University

Extracorporeal affinity adsorption (ECAT) is a method that safely and efficiently reduces dose limiting toxicity associated with the administration of monoclonal antibodies conjugated with a cytotoxic payload. We have shown that in combination with ECAT higher doses of both radiolabeled (90Y and 177Lu) and drug-conjugated (auristatin) antibodies can be increased without increase of toxicity. During ECAT the circulating antibodies remaining in the blood is removed by in-line passage of the blood through an affinity adsorbent.

Antibody Engineering Programs

Novel Antibody Constructs & Alternative Scaffolds

Cancer Biotherapeutics

Development of Novel Biotherapeutics

Protein Expression Programs

High-Throughput Protein Expression

Optimizing Protein Expression

Difficult to Express Proteins